Science Pool

Ad hoc: Evotec SE – Bayer discontinues clinical development candidate eliapixant (BAY1817080); Evotec regains the rights to all P2X3 assets

Evotec SE announces today that the Company has been informed by Bayer about a decision to discontinue the development of the investigational P2X3 receptor antagonist eliapixant (BAY1817080), which stems from a former Evotec/Bayer multi-target research alliance.

Read More